ISSCR 2022 | Corning

We hope you had a chance to visit Corning at ISSCR 2022 to see the latest solutions for stem cell research, including an expanded offering in 3D cell culture. Even if we missed you at the meeting, we invite you to learn more about our solutions we featured in our exhibit, including:

• 3D Cell Culture, including spheroids, organoids, tissue models, and advanced 3D technologies such as the New Corning^® Matribot^® Bioprinter
• Advanced therapy scale-up workflow tools for seed train, expansion and processing, harvest and cryopreservation
• Solutions for cancer research
• Sample cooling and freezing
• Lab automation tips and microplates that support assay development and target ID to screening to high throughput screening

Austin Mogen, Ph.D.

Senior Field Applications Scientist, Corning Life Sciences

Dr. Austin Mogen is a Senior Field Application Scientist at Corning Life Sciences. He received his doctorate from the University of Florida and gained industry experience as a Senior Scientist of upstream process development and manufacturing supervisor for viral vector manufacturing. In this position he focused on bioprocess development, closed system solutions for cell culture scale-up, and viral vector production. Since joining Corning, Dr. Mogen works extensively with academic researchers and process development groups, optimizing cell culture assays and cellular scale-up conditions for viral production, cellular therapeutics, and biologics.

Sylvia Boj, Ph.D.

Chief Scientific Officer, HUB Organoids 

Sylvia F Boj received her PhD in 2006 at the University of Barcelona, Spain for her work at IDIBAPS on functional genetic analysis for deciphering the transcriptional role of MODY genes in pancreatic beta cells.

With a long term EMBO fellowship, she subsequently joined the Hubrecht Institute (Utrecht, the Netherlands) as a postdoctoral fellow. In the laboratory of Prof. Hans Clevers she first studied the role of TCF7L2 regulating metabolism. Then, she established an in vitro organoid model for human pancreatic cancers. In 2014, she moved to Hubrecht Organoid Technology (Utrecht, the Netherlands) as a group leader for Cystic Fibrosis and Cancer programs. In 2016, she was appointed as Scientific Director of HUB, with the ultimate goal of transferring scientific advances of the Organoid Technology to the development of new drugs, by interacting with pharmaceutical companies, and developing clinical trials to validate the predictive value of the Organoids for the response of patients.